Community

Advertising Opportunities

 Biotechnology Europe Programs

 Resources

Biotechnology Europe Community

Feedback

Contact

Biotechnology Europe Advantages

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

 

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe

Terms of Business

Imprint

Privacy Policy

FAQ

Subscribe Newsletter

 

  BIOTECHNOLOGY EUROPE NEWS    

 

 

 

 
 

 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

post your news I subscribe newsletter I contact us

 
03.09.2010 OvPlex™ launched in Asia  
HealthLinx Limited Singapore distribution partner INEX Innovation Exchange Pte Ltd has launched OvPlex™ in Singapore yesterday. Under the terms of its agreement with HealthLinx, INEX will have the exclusive rights to market, sell and distribute OvPlex™ for a period of ten years. Singapore will serve as the platform to launch into the region including India, Malaysia, Thailand, Indonesia and Vietnam.
   
 
02.09.2010 Anti-Cancer Agent, Xeloda® Filed for Advanced or Refractory Gastric Cancer By “New Drug Application Based on Evidence in the Public Domain”  
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, "Chugai")] announced today that it filed on September 1, a “new drug application (NDA) based on evidence in the public domain” with the Japanese Ministry of Health, Labour and Welfare (MHLW), seeking approval for the indication “advanced or refractory gastric cancer in patients who are not candidates for curative surgery” for the anti-cancer agent capecitabine (brand name: Xeloda® Tablet 300, hereafter, “Xeloda®”). In Japan, Xeloda® is currently marketed for the indications of “inoperable or recurrent breast cancer,” “postoperative adjuvant chemotherapy for colon cancer,” and “advanced or refractory colorectal cancer in patients who are not candidates for curative surgery.”
 
   
 
02.09.2010 MorphoSys Initiates Program Against Drug-Resistant MRSA Infections  
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today a new proprietary development program against novel infectious disease targets. As part of this initiative, MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics, providing access to novel target molecules associated with Staphylococcus aureus infections including MRSA (methicillin-resistant S. aureus). MorphoSys will generate antibodies using its proprietary HuCAL PLATINUM antibody library which Absynth will test in relevant disease models. MorphoSys will be solely responsible for the development and partnering of the resulting compounds. Absynth will receive an upfront payment and is eligible for development-dependent milestone payments and royalties. Further financial details were not disclosed.




   
   
 
 I back I top I  

                                                                

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved